🔗 Share this article

Given that America undertakes unprecedented changes to its vaccine schedules, an unexpected name has emerged in a surprising turn: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 vaccinations in the pandemic and has zeroed in on potential deaths after Covid immunization in her recent time at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Schedule

Health officials had intended to announce sweeping revisions to the pediatric vaccine schedule earlier this month, aligning the US with the Danish immunization schedule, sources say – a major change that would place the US out of step with many the world with little proof for improved outcomes. The announcement has been delayed until the coming year.

In place of the top vaccines chief, Høeg is set to speak at the gathering. She was recently named interim head of the FDA’s drug evaluation center, the fifth person to lead the office this year.

Consolidating Power at the FDA

The acting appointment may indicate a tighter collaboration between the drug and vaccine divisions as Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon rolling back already-approved vaccines at the FDA.

The new acting director has frequently advocated for discontinuing some pediatric shot schedules in the US so as to align more like Denmark, a society with universal health coverage and a number of inhabitants about the size of the state of Wisconsin.

So far comments, she has continued to focus on vaccines – usually the purview of Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Questions Over Expertise

The appointee has no obvious track record in pharmaceutical research, approval processes or management, which has been standard for past directors of the CBER. She has worked at the FDA as a top consultant to the agency head and CBER since March.

“She appears not to have any of the qualifications” for leading the CDER, remarked Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in managing a major agency. She lacks background in drug approvals.”

Previous heads of CBER would “understand legal statutes and the research of medication creation”, said Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that former directors who ran CBER have had.”

The drug center has an immense workload at the FDA, Woodcock emphasized.

“The public just focuses on the novel medication approvals, but the generic program approves numerous off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and so forth, and every single one must be supervised,” Woodcock said. “The thing you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Additionally, a major administrative element to the role, which supervises over 5,000 employees. “It’s a enormous management job, if you do it right,” the former official concluded.

Official Statement and Controversial Initiatives

Regarding inquiries about Dr. Høeg's credentials and whether this selection represents increased cooperation among FDA leaders on immunizations, a representative responded that the “inquiries are based on flawed premises”.

“Her experience aligns with the functions of her job,” the representative explained, pointing to the period Dr. Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Høeg takes over the agency head's controversial fast-track approval initiative, a contentious one-day therapy clearance system that apparently troubled her predecessors. “How are these drugs being selected for this voucher program? Who takes the choices?” Howard asked. “There’s a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards less stringent regulations of pharmaceuticals, except for shots.”

Established Past Work on Immunizations

With immunizations, Høeg has a clearer, if concerning, track record, Howard have noted. She authored a study using non-validated public submissions to estimate the incidence of myocarditis following COVID-19 vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccinations are more dangerous than they are.

Part of her “desired changes” for the incoming government featured revising guidelines for new vaccines and halting “unnecessary” immunizations, she remarked following the vote on a audio program. At the agency, Høeg has reportedly suggested excluding adolescent males from getting Covid vaccinations.

“She’s an complete true believer who commences with her beliefs and reverse-engineers to fit the evidence in a very misleading, fraudulent manner,” Howard argued.

Consolidating Power and a “Push for Payback”

Høeg aligned with other contrarians, {like|